A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, Kakiuchi N, Yoshizato T, Shiozawa Y, Shiraishi Y, Striefler JK, Bischoff S, Lohneis P, Putter H, Blau O, Keilholz U, Bullinger L, Pelzer U, Hummel M, Riess H, Ogawa S, Sinn M, Damm F.
Hoyer K, et al. Among authors: lohneis p.
EBioMedicine. 2021 Apr;66:103327. doi: 10.1016/j.ebiom.2021.103327. Epub 2021 Apr 13.
EBioMedicine. 2021.
PMID: 33862582
Free PMC article.
Clinical Trial.